Literature DB >> 16918227

Intrathecal baclofen therapy and multiple sclerosis: outcomes and patient satisfaction.

John R Vender1, Mary Hughes, Betsy D Hughes, Sydney Hester, Stephen Holsenback, Brenda Rosson.   

Abstract

OBJECT: In this study the authors provide an assessment of intrathecal baclofen (ITB) therapy and evaluate patient outcomes and satisfaction.
METHODS: Records for patients with multiple sclerosis who were selected as candidates for ITB therapy were reviewed for their response to test dose, surgical technique, surgery- and pump-related complications, and short- and long-term response to therapy. Family and caregiver assessments of the value of ITB therapy were also reviewed.
CONCLUSIONS: Intrathecal baclofen therapy is safe and effective. Most patients and caregivers express satisfaction with the therapy and would recommend it to other patients. Spasm frequency appears to be the single most common variable positively affected by therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16918227     DOI: 10.3171/foc.2006.21.2.7

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  1 in total

1.  Intrathecal baclofen for spasticity management: a comparative analysis of spasticity of spinal vs cortical origin.

Authors:  April Saval; Anthony E Chiodo
Journal:  J Spinal Cord Med       Date:  2010       Impact factor: 1.985

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.